www.idosr.org Mpora, 2026

©IDOSR PUBLICATIONS

ISSN: 2579-079X

International Digital Organization for Scientific Research IDOSR JST/26/1220000
IDOSR JOURNAL OF SCIENCE AND TECHNOLOGY 12(2):47-52, 2026.
https://doi.org/10.59298/IDOSR/JST/26/122.4752

Smart Nanodelivery Systems for Herbal Anti-Obesity Agents: Controlled Release and Metabolic Reprogramming

Mpora Kakwanzi Evelyn

Department of Pharmacognosy Kampala International University Uganda
Email: evelyne.mpora@studwc.kiu.ac.ug

ABSTRACT

Herbal anti-obesity agents provide multi-target modulation of appetite signaling, adipose inflammation, lipid handling, insulin sensitivity, and gut–brain–liver axis communication. However, their translation into reliable therapies is limited by poor aqueous solubility, chemical instability, extensive first-pass metabolism, efflux transport, and variability in botanical composition and microbiome-driven biotransformation. Smart nanodelivery systems aim to overcome these constraints by combining nanoencapsulation with controlled or stimuli-responsive release, improved mucosal residence, and redesigned biodistribution. By stabilizing exposure and aligning release kinetics with pathway-level objectives, these systems can support metabolic reprogramming rather than transient symptomatic effects. Mechanistically, sustained delivery can dampen adipose inflammatory signaling, normalize lipolysis, suppress pathological adipogenesis, improve hepatic lipid metabolism, and promote thermogenic and mitochondrial programs, while gut-targeted release can reshape microbiota-derived metabolites and bile acid signaling that influence energy balance. Smart designs include pH- and enzyme-responsive matrices for region-specific intestinal release, redox-responsive systems for intracellular payload liberation, and composite carriers that enable sequential or co-delivery of complementary phytochemicals. Yet obesity is a chronic-use indication; therefore, long-term safety, manufacturability, reproducible characterization, and clear PK–PD linkage to clinically meaningful endpoints remain decisive. This review evaluates smart nanodelivery strategies for herbal anti-obesity agents, emphasizing controlled release as a driver of durable metabolic reprogramming and outlining translational challenges and development priorities.
Keywords: smart nanodelivery; herbal medicine; controlled release; obesity; metabolic reprogramming

INTRODUCTION

Obesity is a chronic, relapsing metabolic disease shaped by excess adipose expansion, systemic low-grade inflammation, impaired insulin signaling, altered lipid flux, mitochondrial dysfunction, and dysregulated appetite and reward circuits[1–3]. Although recent pharmacotherapies have improved weight-loss efficacy, long-term management remains challenged by access, tolerability, variable response, and the need for sustained adherence[4–6]. Moreover, obesity-related morbidity is not fully explained by body weight alone; adipose tissue inflammation, hepatic steatosis, and cardiometabolic risk can persist even with modest weight reduction. These realities sustain interest in adjunctive interventions that improve metabolic tissue biology and reduce inflammation while remaining safe for chronic use[7, 8].

Herbal anti-obesity agents and plant-derived phytochemicals have been used across traditional medical systems to reduce appetite, improve digestion, and restore metabolic balance. Modern studies suggest that many herbal bioactives modulate key pathways relevant to obesity, including suppression of adipogenesis, normalization of lipolysis, promotion of fatty acid oxidation, induction of browning and thermogenesis, reduction of oxidative stress and inflammatory cytokine signaling, and modulation of gut microbiota and bile acid signaling[9–11]. This pleiotropy is attractive because obesity is a systems-level disorder with multiple reinforcing loops. However, clinical translation has often been inconsistent. The dominant reasons are pharmacokinetic and formulation-related: many phytochemicals are poorly water-soluble, chemically unstable, rapidly metabolized, and subject to efflux transporters, resulting in low and variable exposure after oral dosing[12]. Botanical variability and microbiome-driven metabolite diversity further amplify heterogeneity in response.

Nanodelivery offers a way to convert mechanistic promise into predictable exposure. Conventional nanoencapsulation strategies improve solubility, protect labile compounds, and sometimes enhance absorption, but "smart" nanodelivery systems go further[13, 14]. Smart systems are designed to control when, where, and how payloads are released and to align release behavior with biological targets. For obesity, this matters because durable benefit typically requires sustained pathway engagement and tissue-level remodeling rather than transient signaling perturbations. Short-lived peaks of exposure may produce modest acute effects but fail to reprogram adipose inflammation, hepatic lipid metabolism, or gut-derived endocrine signaling. Controlled release can sustain submaximal but persistent pathway modulation, potentially enabling metabolic reprogramming over weeks to months[13].

Metabolic reprogramming in obesity can be defined as shifting tissue networks from a storage-dominant, inflamed, insulin-resistant state toward improved mitochondrial function, normalized lipid flux, reduced inflammatory tone, and healthier endocrine signaling[15]. In adipose tissue, this involves reducing macrophage-driven cytokine signaling, restoring insulin-mediated control of lipolysis, and improving adipokine profiles. In liver, it includes suppressing de novo lipogenesis, improving fatty acid oxidation, and reducing steatosis-associated inflammation[15]. In skeletal muscle, improved mitochondrial efficiency and glucose uptake contribute to systemic insulin sensitivity. In the gut, changes in microbiota composition, bile acid pools, and gut hormone signaling can influence appetite, inflammation, and energy expenditure. Herbal agents can influence all of these domains, but only if exposure is consistent and aligned with the locus of action.

Smart nanodelivery designs can be tailored to obesity biology in several ways. Region-specific release in the distal intestine or colon can amplify gut-mediated mechanisms by increasing local exposure where microbiota and bile acid signaling are most relevant[16–18]. pH-responsive matrices can protect phytochemicals in gastric conditions and release them in the intestine. Enzyme-responsive systems can exploit microbial enzymes for colon delivery, aligning release with microbiota-related mechanisms. Redox-responsive carriers can facilitate intracellular release in oxidative or glutathione-rich environments, potentially enhancing activity in immune cells or metabolically stressed tissues[19]. Composite nanoparticles can be designed for sequential release, delivering one agent rapidly to modulate absorption or appetite signaling and another more slowly to reprogram adipose inflammation and hepatic lipid handling. Co-delivery systems can stabilize ratios of synergistic phytochemicals, reducing dose burden and increasing consistency compared with separate supplements.

Despite promise, translation requires caution. Obesity therapy is chronic, so the safety bar is high. Smart systems often add complexity through responsive polymers, functional ligands, or multi-layer architectures. Each added feature can increase manufacturing variability and regulatory burden[12, 20]. Moreover, some strategies that enhance permeability or prolong mucosal residence may carry long-term risks if they perturb barrier integrity or cause chronic irritation. Therefore, the most translatable smart designs are those that offer clear mechanistic value with minimal added complexity, use biocompatible and biodegradable materials, and maintain reproducible critical quality attributes at scale.

This review focuses on smart nanodelivery systems for herbal anti-obesity agents, emphasizing controlled release as a tool for metabolic reprogramming. We examine why controlled release is biologically relevant in obesity, discuss major smart design classes and their alignment with gut–liver–adipose biology, and address translational challenges including safety, standardization of herbal payloads, manufacturing, and clinical trial design.

2. Why Controlled Release Matters for Herbal Anti-Obesity Therapy

Controlled release is not a cosmetic improvement; it is a mechanistic lever that can change biological outcomes. Obesity involves slow-changing tissue states, such as chronic inflammation and mitochondrial dysfunction, that typically require sustained pathway modulation to reverse. Herbal bioactives often act through transcriptional and signaling networks that respond to duration and consistency of exposure. For example, suppression of adipogenic programs or induction of thermogenic gene expression depends on time-dependent reprogramming rather than momentary receptor activation[21]. Similarly, normalization of lipolysis often requires improved insulin sensitivity and reduced inflammatory signaling, both of which evolve over time.

Uncontrolled oral dosing of phytochemicals frequently produces low peaks and rapid decline, with high inter-day variability driven by meals, gut transit, and metabolism. This pattern is poorly suited to metabolic reprogramming[22]. Controlled release can smooth exposure, reduce peak–trough swings, and maintain tissue-relevant concentrations longer, which may improve the probability of durable pathway engagement. It can also reduce dose burden and improve adherence, important in long-term obesity management.

Controlled release can also support mechanism localization. If a herbal agent acts primarily in the gut through microbiota modulation or bile acid signaling, controlled release in the distal intestine or colon can sustain local exposure without requiring high systemic absorption[22]. Conversely, if systemic adipose or hepatic actions are dominant, sustained systemic exposure may be required, and release control can reduce the need for frequent dosing. The central principle is aligning release kinetics and location with the intended biology[23].

3. Smart Nanodelivery Designs: Stimuli-Responsive and Programmable Release

Smart nanodelivery systems include designs that release payloads in response to physiological triggers. pH-responsive systems are among the most practical for oral herbal agents because they exploit the natural pH

gradient from stomach to intestine[24]. Protective coatings can limit release in acidic gastric environments and promote release in the small intestine, improving stability and exposure.

Enzyme-responsive systems are particularly relevant for obesity because they can leverage intestinal or microbial enzymes to trigger release in specific gut regions[24]. Polysaccharide-based matrices that are degraded by colonic microbiota can deliver herbal payloads to the colon, where microbiota-mediated mechanisms and bile acid transformations are prominent. This approach can strengthen gut–brain and gut–liver signaling effects while limiting systemic exposure.

Redox-responsive systems aim to enhance intracellular release in environments with high glutathione or oxidative gradients, potentially increasing activity within immune cells or metabolically stressed tissues[25]. While conceptually attractive for targeting inflamed adipose immune niches, the translational challenge is ensuring predictable triggering without off-target release.

Programmable designs also include multi-layer or core–shell systems that allow sequential release. These can be useful when combining herbal agents with different time scales of action, such as an early-phase gut-active component and a longer-acting systemic anti-inflammatory component[26]. The translational value of programmability depends on whether the release pattern produces measurable improvements beyond simpler sustained-release systems.

4. Metabolic Reprogramming Targets and How Smart Delivery Can Engage Them

Metabolic reprogramming in obesity involves coordinated improvements across adipose tissue, liver, muscle, and gut. In adipose tissue, a major goal is reducing macrophage-driven inflammation and restoring insulin-mediated control of lipolysis, thereby reducing fatty acid spillover and ectopic lipid deposition. Sustained delivery of anti-inflammatory and antioxidant herbal compounds may help shift cytokine tone and improve adipokine profiles, supporting improved systemic insulin sensitivity[15, 27, 28].

In liver, reducing de novo lipogenesis and improving fatty acid oxidation are central for obesity-associated steatosis. Controlled systemic exposure to lipid-modulating herbal agents may improve hepatic lipid handling over time, while gut-targeted systems that influence bile acid signaling can modulate hepatic metabolism indirectly[29]. In muscle, improved mitochondrial efficiency and glucose uptake contribute to systemic benefits, though achieving meaningful muscle exposure is challenging and requires careful formulation strategies.

Thermogenesis and browning represent another reprogramming axis, where sustained signaling can support induction of beige adipocyte programs and improved mitochondrial function[30]. Controlled release may help maintain the transcriptional drive needed for browning rather than producing transient signals that fail to shift adipose phenotype. Gut-targeted release can also influence thermogenic signaling through microbiota-derived metabolites and bile acid-mediated endocrine pathways, offering a potentially safer route than systemic sympathetic stimulation[30].

Smart delivery thus supports reprogramming by sustaining exposure, localizing action to the gut when appropriate, and potentially enabling intracellular release in relevant cell types. Translational success depends on demonstrating that these delivery-driven changes translate into durable changes in metabolic biomarkers and clinically meaningful outcomes.

5. Platform Choices for Smart Delivery and Their Translational Trade-Offs

Smart release behavior can be implemented across multiple carrier classes. Lipid-based nanoparticles and nanoemulsions are well suited for solubility-limited herbal compounds and can be combined with protective coatings to influence release site[31, 32]. Polymeric nanoparticles offer tunable degradation and controlled release, making them attractive for sustained systemic exposure. Biopolymer matrices, particularly polysaccharides, are highly relevant for enzyme- and microbiota-responsive release in distal gut regions. Micelles can solubilize hydrophobic agents, but maintaining stability upon dilution and during transit is essential[32]. Nanocrystals are less "smart" in responsiveness but can be paired with coatings to achieve pH-dependent or delayed release while maintaining low excipient burden.

The key trade-off is complexity. Each added responsive feature can increase manufacturing variability and regulatory burden. Therefore, smart designs must earn their complexity by producing measurable improvements in exposure consistency, tissue engagement, or biomarker outcomes relative to simpler formulations[33]. In obesity, where chronic use is required, conservative materials and reproducible production are especially important. The most translatable smart systems are often those that use well-established excipients and exploit robust physiological triggers like pH and microbial enzymatic activity rather than highly sensitive triggers that may vary widely between individuals[33].

6. Translational Challenges: Safety, Standardization, PK–PD, and Clinical Evidence

Long-term safety is the primary translational hurdle for smart nanodelivery in obesity. Formulations designed to enhance mucosal residence or permeability must demonstrate no chronic barrier disruption or gastrointestinal irritation[34–36]. Materials must be biodegradable or safely cleared, and excipient loads must be appropriate for daily dosing. Because herbal agents and delivery systems can influence the microbiome, long-term monitoring of microbiome stability and gastrointestinal symptoms is relevant, particularly for enzyme-responsive colon-targeted systems.

Standardization of herbal payloads is equally critical. Botanical variability can change active content and alter release behavior if the payload composition affects encapsulation or stability. Therapeutically credible products

require standardized extracts or defined phytochemical compositions with validated analytical fingerprints and stability-indicating assays[37, 38].

PK–PD linkage remains a frequent evidence gap. Smart delivery claims often focus on design intent rather than demonstrated in vivo behavior. Translation requires biorelevant release testing, in vivo exposure measurement including metabolites, and linkage to mechanistic biomarkers in adipose, liver, and gut. Clinically meaningful endpoints should include fat mass and waist circumference, insulin sensitivity indices, lipid profiles, inflammatory markers, and hepatic steatosis indicators when relevant. Without this integrated evidence chain, it is impossible to justify smart design complexity in routine care.

7. Future Directions: Minimal-Complexity Smartness and Phenotype-Aware Trials

The next phase of the field will likely prioritize minimal-complexity smart delivery that uses robust physiological triggers and conservative materials. Distal gut targeting using microbiota-degradable biopolymers and pH-protective coatings is particularly promising because it aligns with gut-mediated obesity mechanisms and can reduce systemic exposure while maintaining efficacy. Sustained-release systemic formulations may be prioritized for agents targeting hepatic lipid metabolism and adipose inflammation, especially when consistent tissue exposure is required.

Clinical translation will benefit from phenotype-aware trial design. Obesity is heterogeneous, and response to herbal agents may depend on baseline inflammation, insulin resistance severity, NAFLD presence, and microbiome configuration. Trials that stratify or at least measure these features can clarify who benefits and why. Comparative studies against optimized non-nano formulations are essential to justify the added complexity of smart nanodelivery. Ultimately, success will depend on demonstrating that controlled release produces durable metabolic reprogramming, improved cardiometabolic risk markers, and acceptable long-term safety at feasible cost and manufacturing scale.

CONCLUSION

Smart nanodelivery systems can convert herbal anti-obesity agents from inconsistent supplements into more predictable, mechanism-aligned interventions by controlling release location and kinetics and enabling sustained pathway engagement. Controlled release is particularly relevant to obesity because durable benefit requires slow tissue reprogramming, including reduced adipose inflammation, normalized lipolysis, improved hepatic lipid handling, and enhanced mitochondrial and thermogenic capacity, while gut-targeted release can reshape microbiota-derived and bile acid–mediated signals that regulate energy balance. However, the chronic nature of obesity therapy demands conservative materials, long-term safety validation, standardized herbal payloads, and reproducible manufacturing. Translational credibility hinges on clear PK–PD linkage demonstrating that smart release behavior occurs in vivo and drives meaningful improvements in fat mass, insulin sensitivity, lipid profiles, inflammatory markers, and hepatic steatosis endpoints where relevant. Minimal-complexity "smartness" that delivers measurable clinical value will define the most successful nanotherapeutic herbal strategies.

REFERENCES

1. Lustig, R.H., Collier, D., Kassotis, C., Roepke, T.A., Kim, M.J., Blanc, E., Barouki, R., Bansal, A., Cave, M.C., Chatterjee, S., Choudhury, M., Gilbertson, M., Lagadic-Gossmann, D., Howard, S., Lind, L., Tomlinson, C.R., Vondracek, J., Heindel, J.J.: Obesity I: Overview and Molecular and Biochemical Mechanisms. Biochem. Pharmacol. 199, 115012 (2022). https://doi.org/10.1016/j.bcp.2022.115012
2. Ahmed, S.K., Mohammed, R.A.: Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metab. Open. 27, 100375 (2025). https://doi.org/10.1016/j.metop.2025.100375
3. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
4. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
5. Anastasiou, I.A., Kounatidis, D., Honka, M.-J., Vallianou, N.G., Rebelos, E., Karamanolis, N.N., Dalamaga, M., Pantos, C., Mourouzis, I.: Metabolomic Alterations in Patients with Obesity and the Impact of Metabolic Bariatric Surgery: Insights for Future Research. Metabolites. 15, 434 (2025). https://doi.org/10.3390/metabo15070434
6. Awari, A., Kaushik, D., Kumar, A., Oz, E., Çadırcı, K., Brennan, C., Proestos, C., Kumar, M., Oz, F.: Obesity Biomarkers: Exploring Factors, Ramification, Machine Learning, and AI-Unveiling Insights in Health Research. MedComm. 6, e70169 (2025). https://doi.org/10.1002/mco2.70169
7. Chadt, A., Scherneck, S., Joost, H.-G., Al-Hasani, H.: Molecular links between Obesity and Diabetes: "Diabesity." In: Feingold, K.R., Ahmed, S.F., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., Hofland, J., Kalra, S., Kaltsas, G., Kapoor, N., Koch, C., Kopp, P., Korbonits, M., Kovacs, C.S., Kuohung, W., Laferrère, B., Levy, M., McGee, E.A., McLachlan, R., Muzumdar, R., Purnell, J., Rey, R., Sahay, R., Shah, A.S., Singer, F., Sperling, M.A.,

Stratakis, C.A., Trence, D.L., and Wilson, D.P. (eds.) Endotext. MDText.com, Inc., South Dartmouth (MA) (2000)
8. Izah, S.C., Betiang, P.A., Ainebyoona, C., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
9. Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L.R., Scaldaferri, F.: Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern. Emerg. Med. 19, 275–293 (2024). https://doi.org/10.1007/s11739-023-03374-w
10. Feng, J.: Role of curcumin in altering gut microbiota for anti-obesity and anti-hyperlipidemic effects. Front. Microbiol. 16, (2025). https://doi.org/10.3389/fmicb.2025.1625098
11. Geng, J., Ni, Q., Sun, W., Li, L., Feng, X.: The links between gut microbiota and obesity and obesity related diseases. Biomed. Pharmacother. 147, 112678 (2022). https://doi.org/10.1016/j.biopha.2022.112678
12. Waterlander, W.E., Singh, A., Altenburg, T., Dijkstra, C., Luna Pinzon, A., Anselma, M., Busch, V., van Houtum, L., Emke, H., Overman, M.L., Chinapaw, M.J.M., Stronks, K.: Understanding obesity-related behaviors in youth from a systems dynamics perspective: The use of causal loop diagrams. Obes. Rev. 22, e13185 (2021). https://doi.org/10.1111/obr.13185
13. Almuraee, A.A.: Nano-formulated herbal bioactives in animal-based functional foods: A nutritional approach to enhancing bioavailability and health benefits. Appl. Food Res. 6, 101587 (2026). https://doi.org/10.1016/j.afres.2025.101587
14. Nwuruku, O.A., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
15. Hartsoe, P., Holguin, F., Chu, H.W.: Mitochondrial Dysfunction and Metabolic Reprogramming in Obesity and Asthma. Int. J. Mol. Sci. 25, 2944 (2024). https://doi.org/10.3390/ijms25052944
16. Emadi, R., Amiri, Z., Moghadam, F.M., Raoufi, S., Moradi, M.Z., Asadi, S., Cho, W.C., Hee Park, J., Voosough, A., Farani, M.R., Hwang, S.-K., Suk Huh, Y.: Self-assembling nanocomposites for smart drug delivery: towards personalized and stimuli-responsive therapeutics. (2026). https://doi.org/10.1039/D5RA07117H
17. Hossen, S., Hossain, M.K., Basher, M.K., Mia, M.N.H., Rahman, M.T., Uddin, M.J.: Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J. Adv. Res. 15, 1–18 (2018). https://doi.org/10.1016/j.jare.2018.06.005
18. Nunziata, G., Pollonio, D., Lacroce, E., Rossi, F.: Smart pH-Responsive polymers in biomedical Applications: Nanoparticles, hydrogels, and emerging hybrid platforms. Mater. Today Chem. 49, 103063 (2025). https://doi.org/10.1016/j.mtchem.2025.103063
19. Singh, H., Balusamy, S.R., Sukweenadhi, J., Saravanan, M., Aruchamy, M., Mijakovic, I., Singh, P.: Smart hybrid nanomaterials for chronic infections: microbiome-responsive and sustainable therapeutic platforms. J. Nanobiotechnology. 23, 698 (2025). https://doi.org/10.1186/s12951-025-03712-4
20. Ajjan, R.A.: The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control. Diabetes Obes. Metab. 26, 3–16 (2024). https://doi.org/10.1111/dom.16098
21. Barros, J., Abraão, A., Gouvinhas, I., Granato, D., Barros, A.N.: Advances in Leaf Plant Bioactive Compounds: Modulation of Chronic Inflammation Related to Obesity. Int. J. Mol. Sci. 26, 3358 (2025). https://doi.org/10.3390/ijms26073358
22. Gómez-Garduño, J., León-Rodríguez, R., Alemón-Medina, R., Pérez-Guillé, B.E., Soriano-Rosales, R.E., González-Ortiz, A., Chávez-Pacheco, J.L., Solorio-López, E., Fernandez-Pérez, P., Rivera-Espinosa, L.: Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals. Dose-Response. 20, 15593258221120485 (2022). https://doi.org/10.1177/15593258221120485
23. Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., Cai, L.: Smart nanoparticles for cancer therapy. Signal Transduct. Target. Ther. 8, 418 (2023). https://doi.org/10.1038/s41392-023-01642-x
24. Bertoni, S., Machness, A., Tiboni, M., Bártolo, R., Santos, H.A.: Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting. Biopolymers. 111, e23336 (2020). https://doi.org/10.1002/bip.23336
25. Jena, A.B., Samal, R.R., Bhol, N.K., Duttaroy, A.K.: Cellular Red-Ox system in health and disease: The latest update. Biomed. Pharmacother. 162, 114606 (2023). https://doi.org/10.1016/j.biopha.2023.114606
26. Uti, D.E., Omang, W.A., Alum, E.U., Bawa, I., Ugwu, O.P.-C., Idowu, A.O., Atangwho, I.J., Egbung, G.E.: Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. Cancer Med. 15, e71519 (2026). https://doi.org/10.1002/cam4.71519
27. Huang, P., Fan, X., Yu, H., Zhang, K., Li, H., Wang, Y., Xue, F.: Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer. J. Transl. Med. 21, 94 (2023). https://doi.org/10.1186/s12967-022-03851-4

28. Miao, L., Miao, R., Yao, Y., Fang, X., Guan, H., Tian, J., Tong, X.: Metabolic reprogramming of pancreatic beta cells in type 2 diabetes and its therapeutic strategy. Ageing Res. Rev. 113, 102938 (2026). https://doi.org/10.1016/j.arr.2025.102938
29. Schiliro, C., Firestein, B.L.: Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells. 10, 1056 (2021). https://doi.org/10.3390/cells10051056
30. Kuryłowicz, A., Puzianowska-Kuźnicka, M.: Induction of Adipose Tissue Browning as a Strategy to Combat Obesity. Int. J. Mol. Sci. 21, 6241 (2020). https://doi.org/10.3390/ijms21176241
31. Subramanian, P.: Lipid-Based Nanocarrier System for the Effective Delivery of Nutraceuticals. Molecules. 26, 5510 (2021). https://doi.org/10.3390/molecules26185510
32. Liu, Y., Liang, Y., Yuhong, J., Xin, P., Han, J.L., Du, Y., Yu, X., Zhu, R., Zhang, M., Chen, W., Ma, Y.: Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs. Drug Des. Devel. Ther. 18, 1469–1495 (2024). https://doi.org/10.2147/DDDT.S447496
33. Saptioratri Budiono, H.D., Nurcahyo, R., Habiburrahman, M.: Relationship between manufacturing complexity, strategy, and performance of manufacturing industries in Indonesia. Heliyon. 7, e07225 (2021). https://doi.org/10.1016/j.heliyon.2021.e07225
34. Ahari, H., Jafari, A., Ozdal, T., Moradi, S., Bahari, H.-R., Wu, Q., Eş, I., Mousavi Khaneghah, A.: Recent innovations in metal-based nanoparticles for food packaging: A focus on safety and environmental impact. Appl. Food Res. 5, 100860 (2025). https://doi.org/10.1016/j.afres.2025.100860
35. De Jong, W.H., Geertsma, R.E., Borchard, G.: Regulatory safety evaluation of nanomedical products: key issues to refine. Drug Deliv. Transl. Res. 12, 2042–2047 (2022). https://doi.org/10.1007/s13346-022-01208-4
36. Ferroni, L., Zavan, B.: Plant-Derived Extracellular Vesicles in Cosmetics: Building a Framework for Safety, Efficacy, and Quality. Cosmetics. 12, (2025). https://doi.org/10.3390/cosmetics12060252
37. Noviana, E., Indrayanto, G., Rohman, A.: Advances in Fingerprint Analysis for Standardization and Quality Control of Herbal Medicines. Front. Pharmacol. 13, (2022). https://doi.org/10.3389/fphar.2022.853023
38. Alum, E.U., Manjula, V.S., Uti, D.E., Echegu, D.A., Ugwu, O.P.-C., Egba, S.I., Agu, P.C.: Metabolomics-Driven Standardization of Herbal Medicine: Advances, Applications, and Sustainability Considerations. Nat. Prod. Commun. 20, 1934578X251367650 (2025). https://doi.org/10.1177/1934578X251367650

CITE AS: Mpora Kakwanzi Evelyn. (2026). Smart Nanodelivery Systems for Herbal Anti-Obesity Agents: Controlled Release and Metabolic Reprogramming. IDOSR JOURNAL OF SCIENCE AND TECHNOLOGY 12(2):47-52, 2026. https://doi.org/10.59298/IDOSR/JST/26/122.4752